A partial length recombinant IMPDHII protein (amino acids 48-351) was used as the immunogen for this antibody.
Alternative Names:
IMPDH2||IMPD2
IMPDH2 (Human type II inosine monophosphate dehydrogenase) is a key enzyme in the purine nucleotide biosynthetic pathway and constitutes a pivotal biological target for immunosuppressant and antiviral drugs. The enzymatic reaction involves the NAD-dependent oxidation of inosine-5-monophosphate into xanthine-5-monophosphate, which is then converted into guanosine-5-monophosphate. It is increased more than 10-fold in activated peripheral blood T lymphocytes and is required for T cell activation. Type II isoform of the enzyme is selectively upregulated in neoplastic fast replicating lymphocytes and CML cancer cells. Thus, the IMPDH2 is an excellent target for antileukemic agent.
